Clinical trials: Placebo Response
Ulcerative Colitis
Efficacy and Safety of Orally Administered BBT-401-1S in Subjects With Ulcerative Colitis
This is a randomised, double-blind, placebo-controlled, proof of clinical principle study to explore the efficacy and safety of orally administered BBT-401-1S in subjects with ulcerative colitis.
- Trial name
- NCT04596293
- Where
- 30 sites in United States, Poland and 2 more
- Volunteers
- 38 people
- Sponsor
- Bridge Biotherapeutics, Inc.
Parkinson's Disease
A Study to Investigate the Tolerability and Effect of Three Single-dose Regimens of BIA 9-1067
The purpose of this study is to investigate the effect of BIA 9-1067 on the levodopa pharmacokinetics when administered in combination with immediate release levodopa/carbidopa or levodopa/benserazide in Parkinson's Disease (PD)…
- Trial name
- NCT01568034
- Testing
- BIA 9-1067, Levodopa/Carbidopa, Levodopa/Benzerazide
- Where
- 3 sites in Portugal, Romania and 1 more
- Volunteers
- 10 people
- Sponsor
- Bial - Portela C S.A.
Rheumatoid Arthritis
Dose-finding Study of GLPG0634 as Monotherapy in Active Rheumatoid Arthritis (RA) Participants (DARWIN2)
Participants suffering from active rheumatoid arthritis who had an inadequate response to methotrexate were evaluated for improvement of disease activity (efficacy) when taking GLPG0634 as monotherapy (3 different doses - 50…
- Trial name
- NCT01894516
- Testing
- GLPG0634
- Where
- 82 sites in United States, Argentina and 17 more
- Volunteers
- 287 people
- Sponsor
- Lakefront Biotherapeutics NV
Gastroesophageal Reflux Disease (GERD), Heartburn
Response to Supplement and Placebo in GERD
The purpose of this study is to investigate the effects of a widely available over the counter supplement marketed for heartburn symptoms on symptoms and health-related quality of life in patients with gastroesophageal reflux…
- Conditions
- Gastroesophageal Reflux Disease (GERD), Heartburn, Dyspepsia
- Trial name
- NCT01915173
- Testing
- Supplement, Expanded Interview, Standard Interview
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Beth Israel Deaconess Medical Center
Chronic Obstructive Pulmonary Disease
Study to Investigate the Dose Response, Safety and Efficacy of Nebulized EP-101(SUN101) in Patients With Chronic Obstructive Pulmonary Disease (COPD): GOLDEN-1 Study
The purpose of this study is to determine steady-state efficacy and dose response profile and to assess safety and pharmacokinetic profile of nebulized EP-101(SUN101) after 7-day dosing using an investigational high efficiency…
- Trial name
- NCT01426009
- Testing
- EP-101 via nebulizer (eFlow®) 25 ug, EP-101 via nebulizer (eFlow®) 50 ug, EP-101 via nebulizer (eFlow®) 100 ug
- Where
- 11 sites in United States, United Kingdom
- Volunteers
- 140 people
- Sponsor
- Sunovion Respiratory Development Inc.
HIV Infection
Analytical Treatment Interruption (ATI) to Assess the Immune System's Ability to Control HIV in Participants Who Became HIV-infected During the HVTN 704/HPTN 085 AMP Study
The purpose of this study is to learn whether having the AMP Study antibody (called VRC01) in a person's body might help their immune system control HIV better, even without HIV medication called antiretroviral therapy or ART, if…
- Trial name
- NCT04801758
- Testing
- Analytical Treatment Interruption
- Where
- 6 sites in Brazil, Peru
- Volunteers
- 18 people
- Sponsor
- HIV Vaccine Trials Network
Osteoarthritis Knee Pain
A Study Comparing Duloxetine Versus Placebo in Patients Taking a Nonsteroidal Anti-inflammatory Drug (NSAID) for Knee Pain Due to Osteoarthritis
The study will test the hypothesis that, in patients with knee pain due to osteoarthritis (OA) who are taking nonsteroidal anti-inflammatory drugs (NSAIDs) but still have significant knee pain, duloxetine 60 to 120 milligrams…
- Trial name
- NCT01018680
- Testing
- Duloxetine
- Where
- 35 sites in United States, Puerto Rico
- Volunteers
- 524 people
- Sponsor
- Eli Lilly and Company
Primary Open Angle Glaucoma, Ocular Hypertension
Ph2 Placebo-Controlled Study for Safety & Ocular Efficacy of SBI-100 Ophthalmic Emulsion in Pts w/ Elevated Eye Pressure
The goal of this clinical trial is to test in patients with glaucoma and elevated pressure in the eye. The main questions it aims to answer are: • ability to lower pressure in the eye • safety in the eye and the body of patients…
- Trial name
- NCT06144918
- Testing
- SBI-100 Ophthalmic Emulsion, 0.5%, SBI-100 Ophthalmic Emulsion, 1.0%
- Where
- 3 sites in United States
- Volunteers
- 56 people
- Sponsor
- Skye Bioscience, Inc.
Pulmonary Disease, Chronic Obstructive
A Randomized, Double Blind, Placebo Controlled, Incomplete Block, Crossover, Dose Ranging Study to Evaluate the Dose Response of GSK573719 Administered Once or Twice Daily Over 7 Days in Patients With Chronic Obstructive Pulmonary Disease (COPD)
The purpose of this study is to further characterize the dose response of GSK573719 at doses of 15.6 micrograms (mcg) to 125 mcg once daily in patients with chronic obstructive pulmonary disease (COPD).
- Trial name
- AC4115321 (NCT01372410)
- Testing
- GSK573719, Tiotropium
- Where
- 13 sites in United States
- Volunteers
- 163 people
- Sponsor
- GlaxoSmithKline
Asthma
A Study to Evaluate the Effect of GW870086X on Allergen Challenge in Mild Asthmatics
The study will measure the early and late asthamtic response using an allergen challenge. This study will evaluate the safety and patients tolerance to repeat inhaled doses of GW870086X using a number of clinical and biological…
- Trial name
- NCT00857857
- Testing
- GW870086X, FP
- Where
- 4 sites in Germany
- Volunteers
- 24 people
- Sponsor
- GlaxoSmithKline
Malaria
Safety, Immunogenicity, and Protective Efficacy of Radiation Attenuated Plasmodium Falciparum NF54 Sporozoites (PfSPZ Vaccine) During Malaria Transmission Season in Healthy African Adult Women of Childbearing Potential in Mali
Background: Malaria is a disease spread by mosquitos. Pregnant women are highly susceptible to malaria. This can lead to poor health outcomes for pregnant women and their babies.
- Trial name
- NCT03989102
- Testing
- PfSPZ Vaccine, Normal Saline
- Where
- Mali
- Volunteers
- 324 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Rheumatoid Arthritis
A Study of Rituximab (MabThera®/Rituxan®) in Patients With Rheumatoid Arthritis and Inadequate Response to Methotrexate
This 3 arm study assessed the efficacy of rituximab (MabThera®/Rituxan®) in the prevention of progression of structural joint damage in participants with active rheumatoid arthritis who had an inadequate clinical response to…
- Trial name
- SCORE (NCT00578305)
- Testing
- Rituximab, Methylprednisolone, Methotrexate
- Where
- 60 sites in Argentina, Brazil and 17 more
- Volunteers
- 185 people
- Sponsor
- Hoffmann-La Roche
Primary Biliary Cirrhosis (PBC)
Study to Evaluate the Effects of Two Doses of Seladelpar (MBX-8025) in Subjects With Primary Biliary Cirrhosis (PBC)
The primary objective of this study is to evaluate the effect of seladelpar (MBX-8025) on alkaline phosphatase (AP) levels in participants with primary biliary cirrhosis (PBC).
- Trial name
- NCT02609048
- Testing
- Experimental: Seladelpar 50 mg, Experimental: Seladelpar / MBX-8025 200 mg
- Where
- 49 sites in United States, Canada and 3 more
- Volunteers
- 41 people
- Sponsor
- Gilead Sciences
Rheumatoid Arthritis
Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis (RA) and an Inadequate Response to Anti-Tumor Necrosis Factor α (Anti-TNFα) Agents (CAIN457F2309 and CAIN457F2309E1)
The core and extension studies assessed the safety and efficacy of secukinumab when added to a background therapy in patients with active rheumatoid arthritis who are intolerant to or have had an inadequate response to anti-TNF-α…
- Trial name
- NURTURE 1 (NCT01350804)
- Testing
- AIN457, Abatacept
- Where
- 117 sites in United States, Brazil and 13 more
- Volunteers
- 551 people
- Sponsor
- Novartis Pharmaceuticals
Systolic Hypertension
An 8-week Study to Evaluate the Dose Response of AHU377 in Combination With Valsartan 320 mg in Patients With Mild-to-moderate Systolic Hypertension
The purpose of the study is to evaluate dose response of blood pressure lowering for 4 doses of AHU377, given once daily (50 mg, 100 mg, 200 mg and 400 mg) in combination with a fixed dose of valsartan (320 mg).
- Trial name
- NCT01281306
- Testing
- LCZ696, Valsartan, AHU377
- Where
- 90 sites in United States, Argentina and 7 more
- Volunteers
- 910 people
- Sponsor
- Novartis Pharmaceuticals
Major Depressive Disorder
Adjunctive Mixed Salts Amphetamine for Depressed Adults With Incomplete Response to Current Antidepressant Therapy
In this Phase 4 trial we will study the safety, tolerability and efficacy of mixed salts amphetamine (MSA), trade name Adderall, augmentation of antidepressant therapy for Major Depressive Disorder (MDD) in depressed outpatient…
- Trial name
- NCT02058693
- Testing
- mixed salts amphetamine
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- Rush University Medical Center
Primary Dysmenorrhea
Effect of KYG0395 on Primary Dysmenorrhea
The purpose of this study is to further assess the efficacy, safety and dose-response of KYG0395 in the treatment of primary dysmenorrhea.
- Trial name
- NCT01588236
- Testing
- high dose KYG0395, lower dose KYG0395
- Where
- 23 sites in United States
- Volunteers
- 280 people
- Sponsor
- Jiangsu Kanion Pharmaceutical Co., Ltd
Insomnia Disorder
Efficacy and Safety of ACT-541468 in Elderly Subjects With Insomnia Disorder
This study evaluates the dose response of ACT-541468 on the change of wake after sleep onset (WASO) assessed by polysomnography (PSG) on the first 2 days of each treatment period.
- Trial name
- NCT02841709
- Testing
- ACT-541468
- Where
- 10 sites in United States, Germany
- Volunteers
- 58 people
- Sponsor
- Idorsia Pharmaceuticals Ltd.
Epidermolysis Bullosa
A Phase 2 Study on Effect of Thymosin Beta 4 on Wound Healing in Patients With Epidermolysis Bullosa
The purpose of this study is to investigate a treatment to enhance the healing of acute and chronic nonhealing cutaneous wounds, such as the erosions experienced by patients with Epidermolysis Bullosa (EB), by the known activity…
- Trial name
- NCT00311766
- Testing
- Thymosin Beta 4
- Volunteers
- 30 people
- Sponsor
- RegeneRx Biopharmaceuticals, Inc.
Rheumatoid Arthritis
A Study in Participants With Rheumatoid Arthritis
The primary purpose of this study is to help answer if LY2127399 is safe and effective in the treatment of rheumatoid arthritis in participants with an inadequate response to one or more tumor necrosis factor-alpha (TNF-α)…
- Trial name
- FLEX V (NCT01202773)
- Testing
- LY2127399
- Where
- 201 sites in United States, Argentina and 17 more
- Volunteers
- 456 people
- Sponsor
- Eli Lilly and Company